Intel stock extends gains after report of possible U.S. government stake
IRVINE, Calif. - Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a clinical-stage biotech company with a market capitalization of $188 million, will host a conference call and webcast on Wednesday, August 6, 2025, at 4:30 p.m. ET to discuss new clinical data from its ongoing open-label Phase 1b study of tegoprubart for kidney transplant rejection prevention. The announcement comes as the stock has experienced a significant 20% decline over the past week, though analysts maintain price targets between $8-12.
The data, which includes results from approximately 30 kidney transplant recipients, will be presented at the World Transplant Congress in San Francisco on the same day.
Tegoprubart is an anti-CD40L antibody that targets the CD40 Ligand, which plays a central role in immune cell activation and function. The drug is being developed as a non-lymphocyte depleting, immunomodulatory treatment.
Interested parties can access the conference call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers using conference ID 34575. A webcast will also be available on the company’s website.
In addition to kidney transplantation, Eledon is conducting studies of tegoprubart in xenotransplantation and amyotrophic lateral sclerosis (ALS).
The information in this article is based on a company press release statement.
In other recent news, Eledon Pharmaceuticals disclosed a net loss of $0.08 per basic share for the first quarter of 2025. This development follows the company’s presentation at the World Transplant Congress, where updated clinical data from its ongoing Phase 1b study of tegoprubart for kidney transplant rejection prevention was showcased. The presentation featured results from approximately 30 kidney transplant recipients. Cantor Fitzgerald has reiterated its Overweight rating on Eledon Pharmaceuticals, maintaining a positive stance following a Fireside Chat with the company’s leadership team and an R&D Day focused on tegoprubart. Additionally, H.C. Wainwright assumed coverage on Eledon with a buy rating and a $9.00 price target. Stifel analysts have updated their financial model for Eledon, leading to an improved operating expense forecast and raised earnings per share estimates for 2025 and 2026. These developments indicate continued interest and analysis from the investment community regarding Eledon’s progress and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.